SCHEMBL3409528

SCHEMBL3409528

CC(=O)Nc1ccc(-c2cccc(COC(C)(C)C)c2)cn1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
WNT3A P56704 5/20 0.43
SLC5A1 P13866 2/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CG P48736 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
PTK2 Q05397 1/20 0.41
PARP1 P09874 1/20 0.41
DHODH Q02127 1/20 0.41
USP7 Q93009 1/20 0.40
AOC3 Q16853 1/20 0.40
TDO2 P48775 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27914469 0.84 WNT3A (0.41) SYKCYP4F2CYP4A11WNT3APIK3CD
SCHEMBL15394357 0.78 RXRA (0.50) WNT3APIK3CDPIK3CGABL1BCR
SCHEMBL3415674 0.76 MAP4K4 (0.53) CYP4F2CYP4A11PIK3CD
SCHEMBL27914464 0.75 ATM (0.43) SYKWNT3APIK3CDPIK3CGABL1
SCHEMBL28294579 0.74 KMO (0.52) PIK3CDPIK3CGABL1BCRTDO2
SCHEMBL30338494 0.74 PTK2 (0.57) WNT3APIK3CDPIK3CGPTK2PARP1
SCHEMBL3924054 0.73 ATM (0.48) PIK3CDPIK3CG
SCHEMBL8738131 0.73 KDR (0.55) WNT3APIK3CDPIK3CGABL1BCR
SCHEMBL3920958 0.72 CASR (0.57) WNT3A
SCHEMBL3933758 0.72 WNT3A (0.44) WNT3AABL1BCRPARP1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN SYK 139/4885CYP4F2 67/4885CYP4A11 125/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN SYK 139/4885CYP4F2 67/4885CYP4A11 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.